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Heterotrimeric G proteins are quintessential signalling switches activated by nucleotide
exchange on Ga. Although activation is predominantly carried out by G-protein-coupled
receptors (GPCRs), non-receptor guanine-nucleotide exchange factors (GEFs) have emerged
as critical signalling molecules and therapeutic targets. Here we characterize the molecular
mechanism of G-protein activation by a family of non-receptor GEFs containing a Ga-binding
and -activating (GBA) motif. We combine NMR spectroscopy, computational modelling and
biochemistry to map changes in Ga caused by binding of GBA proteins with residue-level
resolution. We ﬁnd that the GBA motif binds to the SwitchII/a3 cleft of Ga and induces
changes in the G-1/P-loop and G-2 boxes (involved in phosphate binding), but not in the
G-4/G-5 boxes (guanine binding). Our ﬁndings reveal that G-protein-binding and activation
mechanisms are fundamentally different between GBA proteins and GPCRs, and that GEF-
mediated perturbation of nucleotide phosphate binding is sufﬁcient for Ga activation.
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H
eterotrimeric (Gabg) guanine nucleotide-binding
proteins (G proteins) are on/off switches that relay
extracellular signals to intracellular effectors and regulate
a vast array of physiological processes1,2. G-protein activation
is achieved when GDP is exchanged for GTP on the Ga subunit,
a reaction catalysed by guanine-nucleotide exchange factors
(GEFs)3. G-protein-coupled receptors (GPCRs) are the arche-
typical GEFs for heterotrimeric G proteins. Crystal structures4 in
combination with biophysics5–9, biochemistry10,11 and computa-
tional modelling12–14 studies have provided detailed knowledge
on the mechanism by which GPCRs activate G proteins (Fig. 1a).
An obligatory requirement for GPCR-mediated activation is that
GDP-loaded Ga is bound to Gbg. Ligand-occupied GPCRs bind
with low afﬁnity to Gabg-GDP and facilitate GDP release. The
metastable nucleotide-free intermediary forms a high-afﬁnity
complex with GPCRs until GTP is loaded, which in turn
causes (1) dissociation of the GPCR–G protein complex and
(2) dissociation of Ga and Gbg. GTP hydrolysis returns Ga to the
GDP-bound state competent for Gbg binding.
There are also cytoplasmic non-receptor proteins with GEF
activity15–20, which are structurally unrelated to GPCRs and among
themselves. For example, Ric-8 proteins have been extensively
characterized biochemically17,21, and some biophysical and
biochemical studies suggest a mode of action similar to that of
GPCRs22,23. A deﬁned structural module linked to GEF activity has
been described only for a subset of non-receptor GEFs, that is, those
containing a Ga-binding and -activating (GBA) motif16,18–20. This
motif is found in evolutionarily unrelated proteins and mediates
a mechanism of G-protein activation already present in
invertebrates24. The GBA motif is a B30-residue-long sequence
present in the human proteins Ga-interacting, vesicle-associated
protein (GIV also known as Girdin), dishevelled-associating protein
with high frequency of leucines (DAPLE), CALNUC and NUCB2,
which bind and activate Gai proteins (Gai1, Gai2 and Gai3)18–20,25.
GIV and DAPLE are the best-characterized members of this group.
Despite the moderate GEF activity of GIV and DAPLE in vitro, it
has been shown that their GBA motif leads to increased G-protein
activation in cells, as determined by read-outs that monitor either
the formation of Gai-GTP (for example, conformation-speciﬁc
antibodies or cAMP)20,26–28 or free Gbg (for example, PI3K-Akt or
resonance energy transfer-based biosensors)18,20,27,29,30. As
a consequence, they impact cell behaviour, and their dysregulation
is associated with human diseases like cancer, liver ﬁbrosis,
nephrotic syndrome, insulin resistance and pathologic
neovascularization16,20,31. Because inhibiting the GEF activity of
GIV and DAPLE blocks their adverse effects when dysregulated
in pathologic situations16,20,31, disruption of their interaction with
G proteins is emerging as a promising therapeutic strategy31.
G proteins have been crystallized bound to representative
members of every major class of binding partners: GPCRs;
GTPase-activating proteins (GAPs)32; guanine-nucleotide
dissociation inhibitors33 and effectors34,35, but not yet with
non-receptor GEFs. In contrast to GPCRs, GBA proteins activate
monomeric Ga instead of Gabg (refs 18–20,25) and their
mechanism of action remains ill-deﬁned. We set out to
investigate the molecular basis for the GPCR-independent
activation of Gai3 by proteins of the GBA family, and to
establish possible differences and similarities with receptor-
mediated activation. By means of nuclear magnetic resonance
(NMR) spectroscopy, computational modelling and biochemical
assays, we characterize the binding site for GBA proteins and
associated structural changes in Gai3 at the residue level.
Our results provide the ﬁrst detailed view of the molecular
mechanism by which proteins with a GBA motif regulate Gai3,
revealing fundamental differences with GPCR-mediated
activation of G proteins.
Results
GIV binds similarly to GDP-bound and nucleotide-free Gai3.
We focused our initial efforts on GIV, the ﬁrst-identiﬁed
and best-characterized member of the GBA motif-containing
family of non-receptor GEFs. GPCRs bind preferentially
to nucleotide-free G proteins (Ga-[ ]) over G-GDP and dissociate
from G-GTP. We analysed the ability of GIV to bind different
states of Gai3 along the activation pathway, that is,
Gai3-[GDP]-Gai3-[ ]-Gai3-[GTP], by depleting puriﬁed
Gai3 of nucleotides and reloading it (or not) with GDP or
GDP AlF4 (which mimics the GTP-bound transition state;
Fig. 1b). Consistent with previous results18, we found that
GIV binds to Gai3-[GDP] but not to Gai3-[GTP] (Fig. 1b).
Moreover, GIV binds equally to Gai3-[ ] and Gai3-[GDP]
(Fig. 1b). To rule out that this observation was due to inefﬁcient
GDP depletion, we used Ric-8A as a control. The binding
preference of Ric-8A for different states of Gai mimics that
of GPCRs22, that is, Gai3-[ ]444Gai3-[GDP]4Gai3-[GTP].
Ric-8A bound much more to Gai3-[ ] than to Gai3-[GDP]
(Fig. 1b), indicating that nucleotide depletion occurred efﬁciently.
GAIP (also known as RGS19) was used as a control to rule out
that the nucleotide depletion procedure compromised Gai3
integrity. GAIP is a GAP and, as expected36, it bound to
Gai3-[GTP] but not to Gai3-[GDP] (Fig. 1b), demonstrating that
nucleotide-depleted Gai3 can bind nucleotides and adopt an
active conformation. These results indicate that GIV, contrary
to GPCRs, binds to Gai3-[ ] and Gai3-[GDP] to a similar
extent. An independent demonstration that GIV binds similarly
to Gai3-[GDP] and Gai3-[ ] was obtained by co-immuno-
precipitation experiments in mammalian cells. Full-length GIV
co-immunoprecipitated with a G-protein mutant unable to bind
nucleotides, thus mimicking Gai3-[ ]37, as efﬁciently as with the
wild-type (WT) protein (Supplementary Fig. 1). These results
indicate that the association of GIV with G proteins along the
activation pathway differs from that of GPCRs (Fig. 1c):
GIV binds with high afﬁnity to monomeric Gai-[GDP],
remains bound to Gai with similar afﬁnity on nucleotide
release and eventually dissociates on GTP binding to release the
active G protein.
NMR reveals that GIV perturbs discrete regions of Gai3.
A synthetic 16-mer GEF peptide (named KB-752) has been
previously crystallized in complex with Gai1-GDP38. The
sequence of this peptide is not present in any human protein
but has similarity to the GBA motif (Supplementary Fig. 2).
However, comparison of Gai1-GDP free or bound to this peptide
shows that the nucleotide-binding pocket remains essentially
unchanged (Supplementary Fig. 2), providing limited insight into
the mechanism by which GBA proteins activate Gai. This might
be due to loss of structural rearrangements in Gai under
crystallization conditions. To gain further insights into how
a naturally occurring GBA sequence binds to Gai and structural
rearrangements associated with it, we investigated the molecular
mechanism of Gai3 activation by GIV using solution
NMR spectroscopy. Perturbation in the NMR signals of the
backbone amide groups of Gai3 protein on ligand binding
should inform about direct intermolecular contacts as well as
indirect structural rearrangements, providing information at
the residue level.
Full-length GIV is 1,870-amino acid long and is composed
of multiple domains (Supplementary Fig. 2). Attempts to
purify the 4220 kDa full-length protein from bacteria gave
extremely poor yields of low-quality protein, making its use
impossible for NMR experiments. As an experimentally tractable
alternative, we used a C-terminal fragment of GIV corresponding
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to the last 210 amino acids (that is, GIV-CT, residues
1,660–1,870). This fragment was chosen for several reasons:
(i) a thorough characterization of GIV-CT has revealed that it
recapitulates the biological properties of the full-length protein in
mammalian cells, including G-protein-dependent signalling27,29;
(ii) it contains the GBA motif and mutation of this motif in the
context of either full-length GIV or GIV-CT leads to loss of
G-protein binding and G-protein-dependent signalling18,27,29,30;
(iii) GIV-CT is sufﬁcient to bind and activate G proteins
in vitro25, and G-protein binding and/or activation is comparable
to that obtained with larger fragments (for example, residues
1,425–1,870 translated in vitro18 or 1,623–1,870 puriﬁed
from bacteria25). Thus, GIV-CT is a reliable approximation to
the G-protein-binding properties of the native protein and its
signalling functions in cells.
NMR spectra of Gai3-GDP were recorded in the absence or
presence of GIV-CT. Backbone amide signals of Gai3-GDP, as well
as the side chain indol signals of its three tryptophans (W131,
W211 and W258), were assigned in the two-dimensional TROSY
and three-dimensional (3D) HNCO spectra by comparison with
the published assignments under the same experimental condi-
tions39. As expected from the increase in molecular weight and the
binding of a non-deuterated ligand, there was an overall decrease in
signal intensity (medianB3-fold) when NMR measurements were
carried out in the presence of GIV-CT (residues 1,660–1,870,
containing the GBA motif). However, the effect was more
pronounced for certain signals, with some even disappearing
(for example, W211 and W258; Fig. 2a,b). This may be due to
appearance of the signal of the bound form at different frequencies
that we were not able to identify, or to a change in the local
dynamics that broadened the signal beyond detection. Regardless of
the cause, a large intensity loss reﬂects perturbations speciﬁcally
caused by GIV binding and it was quantiﬁed for each signal by the
calculation of the intensity ratio between the free and bound forms
(Iratio). In addition, we measured signiﬁcant chemical shift
perturbations on GIV-CT binding for a fraction (o20%) of the
assigned peaks (Fig. 2a,b). Assignment of the signals in the bound
form was made on a nearest-neighbour basis in both the
two-dimensional and 3D spectra, and was conﬁrmed by the
similar pattern of signals observed in the presence of the shorter
GIV fragment 1,671–1,696 (GIVpept; Supplementary Fig. 3).
Assignments of Gai3-GDP bound to GIVpept were conﬁrmed by
a titration with the peptide. The overall decrease in signal
intensities on binding of GIVpept was only modest (B15%),
which increases the conﬁdence of the identiﬁed perturbations,
especially for the Iratio. The results revealed a high correlation
between the perturbations induced by GIV-CT and GIVpept
(Supplementary Fig. 3c,d), which indicates that the GBA motif of
GIV is causing most of the perturbations observed with GIV-CT.
The similar behaviour observed for the short and long fragments of
GIV is consistent with the disordered nature of the 210-residue-
long C-terminal region of GIV (Supplementary Fig. 4). Circular
dichroism shows little, if any, secondary structure, and no
cooperative transition is observed in the thermal denaturation,
indicating the absence of a tertiary structure. The NMR spectrum
conﬁrms that the C-terminal region of GIV is intrinsically
disordered as the backbone amide signals show very little
dispersion in the proton frequency dimension.
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Figure 1 | GIV binds to GDP-loaded and nucleotide-free Gai3 to a similar extent but does not bind to GTP-loaded Gai3. (a) Sequential steps in
GPCR-mediated activation of G proteins. GPCRs bind with low afﬁnity to Gabg-GDP (1), promote GDP release and form a high-afﬁnity complex with the
nucleotide-free G protein (2) and dissociate on GTP loading (3). Dissociation of the GPCR–G protein complex ensures that the active signalling species
Ga-GTP and free Gbg proceed to act on their effectors. The Ras-like and all-helical domains of Gai3 are shown in light and dark blue, respectively.
(b) GIV binding to Gai3 in different conformations of its activation pathway. Top, Gai3 was nucleotide-depleted and maintained nucleotide-free (Gai3-[ ])
or reloaded with GDP (Gai3-[GDP]) or GDP/AlF4 (Gai3-[GTP]). Bottom, pull-down assays showing equal binding of GIV to Gai3-[ ] and Gai3-[GDP] but
no binding to Gai3-[GTP]. GAIP binds exclusively to Gai3-[GTP] and Ric-8A binds preferentially to Gai3-[ ], followed by weaker binding to Gai3-[GDP]
and dissociation from Gai3-[GTP]21,22. One experiment representative of at least three is shown. (c) Sequential steps in GIV-mediated activation of
G proteins. The substrate for GIV’s GEF activity is monomeric Gai (ref. 18) instead of trimeric Gabg as for GPCRs. In contrast to the steps of
GPCR-mediated activation, GIV binds to Ga already in its GDP-bound conformation (1) and remains bound with similar afﬁnity to the nucleotide-free
conformation after promoting GDP release (2). As in the case of GPCRs, the GEF–G protein complex dissociates on spontaneous loading of
GTP on nucleotide-free Ga (3).
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As a ﬁrst approach to interpret the NMR measurements, which
cannot unambiguously differentiate between direct contacts
and indirect structural rearrangements, we analysed them in
conjunction with molecular modelling. For this, a 3D structural
model of the GBA motif of GIV (residues 1,678–1,696) bound to
Gai3 was built based on homology with the KB-752/Gai1 crystal
structure, ab initio extension of the GBA sequence and docking
(Fig. 3). This model provides independent information because
no constrains based on the NMR data were applied to build it.
Although this model does not capture the possible conforma-
tional changes distant to the peptide-binding site (absent in the
model template), it informs of the protein–protein interface and
provides a framework to visualize what speciﬁc perturbations
might be due to direct GBA binding or indirect conformational
changes. The NMR perturbations mapped predominantly to
the Ras-like domain (Figs 2c and 3, and Supplementary Fig. 3d).
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Figure 2 | NMR mapping of GIV binding on Gai3. (a) Overlay of 1H–15N TROSY spectra of Gai3 free and bound to GIV-CT. Left, 1H–15N TROSY spectra of
2H,13C,15N-Gai3 in the absence (black) or presence of His-GIV-CT (1660–1870) (red). Right, selected regions from the overlaid spectra depicting
representative perturbations in Gai3 signals induced by GIV binding. Some signals (top) exhibit chemical shift changes on GIV binding. Some other signals
(bottom) exhibit marked signal intensity reductions on GIV binding (see text for interpretation). (b) Quantiﬁcation of GIV-induced perturbations of the
NMR signals of Gai3. Chemical shift (CSP, top graph) or intensity perturbations (Iratio,¼ Ibound/Ifree, bottom graph) of the backbone amide signals of the
TROSY NMR spectra in a. Red, orange and yellow circles indicate residues undergoing perturbations larger than 10, 5 or 3 times the median (M),
respectively. Blue circles indicate Gai3 residues with perturbations smaller than three times the median (M) and grey circles residues for which no reliable
NMR measurement could be made. The horizontal black bar in the middle depicts the secondary structure elements of Gai3 derived from our homology
model (see below), and is annotated with the position of the three switch regions (green) that undergo conformational changes on GTP binding and the ﬁve
conserved G-box sequences (blue) that mediate nucleotide binding. (c) Schematic representation of GIV-induced NMR perturbations on Gai3. Gai3
secondary structure elements are depicted with a relative orientation to mimic their position with respect to the nucleotide in the three-dimensional
structure. Colour coding is the same as in b and corresponds to a composite of CSP and Iratio perturbations. For residues in which information for both
CSP and Iratio perturbations was available, the largest of the two was taken. GDP is shown in purple and the interaction between the Switch III of the Ras-like
domain and the aD–aE loop of the all-helical domain is shown in green. The GIV-binding region predicted by modelling is shown in light beige and the
GPCR-binding elements are marked by arrows.
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We observed extensive perturbations in the GIV-binding site
seen in the computational model, which is formed mainly by
the a3 helix, a3/b5 loop and the Switch II (SwII) region
(Figs 2c and 3). There are additional perturbations in the
nucleotide-binding site, which made no direct contact with
GIV in our model. More speciﬁcally, all the residues of the P-loop
and the Switch I (SwI) region for which we could measure
NMR data displayed signiﬁcant perturbations (Figs 2c and 3).
The P-loop and SwI contain the G-1 and G-2 boxes, two of the
ﬁve conserved nucleotide-binding elements of G proteins3. The
G-1/P-loop and G-2/SwI are responsible for binding the
phosphate moieties of GDP, whereas G-4 and G-5 bind
the region of the nucleotide base (G-3 makes direct contact
with GTP but not with GDP). Interestingly, G-4 (that is, b5–aG
loop) and G-5 (b6–a5 loop) remained unperturbed by GIV
binding (Figs 2c and 3). The selective effect of GIV on the
phosphate-binding elements indicates a divergence from the
mechanism of action of GPCRs, which alter all four G-1, G-2, G-4
and G-5 on activation10,11,13. We also observed moderate to
strong perturbations in the interdomain interface of Gai3, that is,
the aD–aE loop (helical domain) and SwIII (Ras-like domain;
Figs 2c and 3). These perturbations are compatible with a local
disruption of the interdomain interface, which might be related to
the domain separation that accompanies increased nucleotide
exchange on the action of both GPCRs4,5,8,10,14 and the
non-receptor GEF Ric-8A (ref. 23).
These results suggest an allosteric mechanism of action for
GIV, whose binding to the a3/SwII cleft induces conformational
changes in the phosphate-binding region of the nucleotide-
binding pocket that weaken GDP binding. The most direct
communication route between the GIV-binding site and the
nucleotide-binding pocket is the b1 strand, which extends from
the bottom of the a3/SwII cleft, where GIV binds, into the P-loop.
Consistent with this hypothesis, the b1 strand undergoes strong
NMR signal perturbations on GIV binding (Figs 2c and 3, and
Supplementary Fig. 3d). This strand has also been proposed to
serve as an allosteric route for GPCR-mediated activation10.
Characterization of Gai3 binding to GIV by mutagenesis. To
further validate the mode of action of GIV on Gai3, we carried
out a biochemical analysis by site-directed mutagenesis.
We reasoned that mutation of residues in direct contact with
GIV should show a larger impact on binding than mutation of
residues involved in indirect structural rearrangements. The
design of the mutants was based on the NMR and modelling data,
but also on in silico thermodynamics analysis of the Gai3–GIV
model, which predicts the Gai3 residues that contribute the most
to the complex formation (Fig. 4a,b). A detailed rationale of the
mutant design is described in Supplementary Note 1. For the
characterization of these mutants, we used puriﬁed His-tagged
Gai3. The tagged protein binds the GBA motif of GIV with the
same afﬁnity as the untagged Gai3 used in the NMR experiments
and is activated to similar levels (Supplementary Fig. 5). All
mutants were puriﬁed with similar yields and purity
(Supplementary Fig. 6a), and were capable of adopting an
active conformation on GTPgS binding (Supplementary Fig. 6b),
indicating that none of them had major structural defects.
We found reduced GIV binding for mutants of any of the
Gai3 residues in SwII, a3 or the a3/b5 loop that were predicted
by the thermodynamics analysis to contribute to GIV binding and
also displaying NMR signal perturbations on GIV binding. These
residues are W211, F215, L249, W258 and F259 (Fig. 4c,d, and
Supplementary Figs 6 and 7). On the other hand, mutation
of V218 or K257, two residues in the same region but predicted
to marginally destabilize GIV binding, had little effect on binding.
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Figure 4 | Characterization of the GIV-binding site on Gai3. (a) GIV-binding site on Gai3 and location of residues selected for mutagenesis. Left,
representation of the molecular model of Gai3 bound to GIVpept (green ribbon) coloured as in Fig. 3. Right, ribbon representation of the view of Gai3 on
the left with residues selected for mutagenesis shown in sticks. (b) Calculation of energetic contribution of individual Gai3 residues to the interaction with
GIV. The Gai3/GIV model was analysed using FoldX. Experimentally mutated residues are indicated with black labels. Residues predicted to stabilize the
interaction but not experimentally tested by mutagenesis are labelled grey. (c) GIV and DAPLE binding to Gai3 mutants in pull-down assays. Binding of His-
Gai3 WTor mutants to immobilized GST-GIV (left) or GST-DAPLE (right) was visualized by Coomassie blue staining. One experiment representative of at
least three is shown. GST protein loading and negative controls are shown in Supplementary Fig. 5. (d) Equilibrium dissociation constants (Kd) for the
binding of Gai3 mutants to the GBA motif of GIV and DAPLE or the GoLoco motif of RGS12. Kd values for ﬂuorescein-labelled peptides derived from GIV,
DAPLE or RGS12 were calculated from ﬂuorescence polarization measurements (complete binding curve data sets in Supplementary Fig. 6). Mean±s.e.m.,
n¼ 3–7. Fold changes in the Kd larger than 2 or smaller than 0.5 are indicated in red or green, respectively. (e) The effect of Gai3 mutations on GIV binding
is highly correlated with DAPLE binding but not with RGS12 binding. Left, heat map (green to red scale shown on top) of Log2 Kd ratios for each Gai3 mutant
relative to WT. Right, correlation plots of Log2(Kd
MUT/Kd
WT) values for GIV and DAPLE (upper right) or GIV and RGS12 (lower right). (f) GIV- and DAPLE-
mediated activation of Gai3 mutants. Steady-state GTPase activity of His-Gai3 WTor mutants in the absence (white) or presence (black) of GIV (left) or
DAPLE (right). Mean±s.e.m., nZ3, **30–50% inhibition, ***450% inhibition of GIV/DAPLE-mediated activation compared to Gai3 WT. Raw basal
activities in the absence of GIV or DAPLE are shown in Supplementary Fig. 7. ND, not determined due to severely compromised basal activity.
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Mutation of S252 and N256, two residues in the a3 helix
displaying large NMR perturbations (Fig. 2) but not predicted to
stabilize GIV binding, severely impaired GIV binding when
mutated to D and E, respectively, but not when mutated to
A (Fig. 4c,d, and Supplementary Figs 6 and 7). These two residues
are located in the GIV-binding site, and mutation to D or E,
respectively, creates a steric/electrostatic hindrance for GIV
binding that does not occur when mutated to A. Mutation of
I184 in SwI also diminished binding (Fig. 4c,d). This residue is
not predicted to contribute directly to GIV binding (Fig. 4a,b) but
makes a direct intramolecular contact with SwII based on our
homology model (Fig. 4a). On the other hand, I184 undergoes
strong NMR signal perturbations in the presence of GIV
(Fig. 2 and Supplementary Fig. 3). This is consistent with
I184 interacting with SwII on GIV binding and possibly
stabilizing a conformation of SwII that favours GIV binding.
These mutagenesis results indicate that the groove formed by a3,
SwII and a3/b5 loop elements is the direct binding site for GIV.
To further characterize the Gai3/GIV-binding site, we analysed a
battery of GIV mutants for binding to Gai3 in a peptide array
format (Supplementary Fig. 8). GBA motif peptides in which nine
selected positions were replaced by every other natural amino acid
one at a time were probed for Gai3 binding (Supplementary
Fig. 8b). Selected mutants were tested for conﬁrmation of binding
in solution (Supplementary Fig. 8C). The results revealed that
mutation of GIV residues predicted by our model to be located in
the vicinity of Gai3 residues important for binding (as determined
by mutagenesis) efﬁciently disrupted the binding. On the other
hand, mutation of residues in the same region of GIV but not
predicted to be important for Gai3, had marginal or no effect on
binding (see Supplementary Note 2 for a full description). These
results further validate our model of GIV binding to a pocket on
Gai3 formed by the a3, SwII and a3/b5 loop.
Mutation of Gai3 residues in the b1/P-loop axis predicted by
the thermodynamics analysis in Fig. 4b to contribute to GIV
binding (K35 and L39) also impaired GIV binding in pull-down
or ﬂuorescence polarization assays (Fig. 4c,d, and Supplementary
Figs 6 and 7). On the other hand, mutation of residues in the
same region and displaying NMR perturbations, but not making
direct contact with GIV (L36, L37 and G42) did not signiﬁcantly
affect binding (Fig. 4c,d). Because G42 is located in the middle of
the P-loop, this suggests that GIV induces indirect structural
rearrangements in the nucleotide-binding pocket.
We monitored GIV-mediated enhancement of Gai3 steady-
state GTPase activity (which reﬂects its GEF activity25) for the
mutants described above. Not all mutants could be analysed due
to compromised intrinsic (basal) activity (Supplementary Fig. 7b),
but the results with the remaining mutants were in excellent
agreement with their relative ability to bind GIV (Fig. 4f). The
activity of selected mutants relative to WT was conﬁrmed by
GTPgS-binding assays, which measure nucleotide exchange more
directly (Supplementary Fig. 7b,c).
Thus, the mutagenesis analysis is highly congruent with the
mode of action suggested by the NMR and molecular modelling
data. Together, these mutagenesis results indicate that
GIV binding and subsequent G-protein activation require residues
located in a pocket of the Ras-like domain where NMR signal
perturbations are clustered (that is, SwII, a3 and a3/b5 loop). On
the other hand, the observation of additional NMR signal
perturbations in residues of the b1/P-loop that are not crucial for
GIV binding point to indirect structural rearrangements associated
with its ability to modulate nucleotide exchange.
Different GBA proteins bind similarly to Gai3. DAPLE has
been recently shown to bind and activate Gai3 via a GBA motif
similar to that in GIV20. We reasoned that if the G-protein-
binding mode of different GBA motifs is conserved, the effect of
speciﬁc Gai3 mutations on DAPLE–Gai3 coupling should closely
recapitulate the observations with GIV–Gai3. Indeed, we found
that the effects of Gai3 mutations in pull-down (Fig. 4c),
ﬂuorescence polarization (Fig. 4d,e) and G-protein activity assays
(Fig. 4f and Supplementary Fig. 7b,c) were highly correlated with
those of GIV. To assess speciﬁcity, we tested the same set of
mutants for binding to a peptide derived from RGS12’s GoLoco
motif. We chose RGS12 GoLoco motif as a stringent test
for speciﬁcity because it also docks onto the a3/SwII cleft of
Gai-GDP33. Consistent with binding to this common site, we
found that some of the mutations that impair GIV binding also
impair binding of the RGS12 GoLoco motif (Fig. 4d,e). However,
the overlap of the sets of Ga mutations that affect binding to
GBA or GoLoco motifs is only partial, and many of the mutations
that affect binding to both motifs do so to a signiﬁcantly different
extent. The divergence of the effect of same Ga mutants on
GoLoco or GBA binding is in agreement with the comparison of
the crystal structures of Gai bound to a GoLoco motif or the
GBA-like peptide KB-752, which showed that the common
binding site formed by the a3 helix and SwII region adopts
a different conformation38. The correlation of the effect of
the entire set of Gai3 mutants on the dissociation constant
of RGS12–Gai3 versus GIV–Gai3 is markedly reduced
(Pearson’s¼ 0.58) compared to the correlation with DAPLE–
Gai3 (Pearson’s¼ 0.97; Fig. 4d,e). A notable example is mutant
W211A, which completely abolishes GIV and DAPLE binding
but has no effect on RGS12 binding. Thus, the overall effect of the
mutants indicates that different GBA proteins share a common
and speciﬁc site of binding to G proteins, which partially overlaps
with the GoLoco-binding site but engages Gai3 in a different way.
GBA proteins and GPCRs couple differently to G proteins.
Figure 5 depicts the mapping of the NMR perturbations
induced by GIV on Gai3 and the GPCR contact sites reported for
a rhodopsin–G-protein model12. Previous studies using
crystallographic, biophysical, biochemical and computational
approaches indicate that GPCRs make contact with the
C-terminal tail of Ga subunits as well as with other regions
such as the boundary between the N-terminal helix (aN) and
the b1 strand, and the a4/b6 loop9–12 (Fig. 5b). These molecular
contacts have been proposed to transmit allosteric confor-
mational changes to the nucleotide-binding pocket via two
distinct routes10,12–14. One route goes through the a5 helix
(which connects the C-terminal tail to the b6/a5 loop that binds
the nucleotide guanine ring) and the other one through the
b1 strand (which connects aN to the P-loop that binds
the nucleotide phosphates; Fig. 5c). Our results suggest that
while GIV induces structural changes along the b1/P-loop axis
(Fig. 5c), it does not perturb signiﬁcantly the C terminus, a5 or
guanine-binding loops (Fig. 5a).
A subset of residues with GIV-induced NMR perturbations
mapped to the a4/b6 loop (Fig. 6a), one of the GPCR-binding
sites, but mutation of two of those residues (R313 and K317) did
not affect Gai3 binding and activation by either GIV or DAPLE
(Fig. 6b–d). These observations indicate the NMR signal
perturbations observed in the a4/b6 loop are likely due to
a secondary structural rearrangement, perhaps mediated by the
a3/b5 loop that directly binds GIV (Fig. 6a). We also tested
a mutant lacking the last nine residues of Gai3 (DC9), which
removes the main GPCR-binding site, and observed no effect on
binding and activation by GIV or DAPLE (Fig. 6b–d).
The results described above indicate that Gai3 mutants
that interfere with GPCR coupling have no effect on how GBA
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proteins couple to Gai3. Next we tested whether the converse
is also true, that is, mutants that disrupt GIV and DAPLE
coupling to Gai3 have no effect on GPCR-mediated G-protein
activation. We used puriﬁed bovine rhodopsin and retinal Gbg
(Gb1g1) in combination with Gai3 mutants (Fig. 7a), a previously
validated system to monitor GPCR-mediated activation of G
proteins in vitro5–7,11,12,40. We selected the Gai3 mutants that
most markedly impair GIV and DAPLE binding (K35A, W211A,
F215A, L249H, S252D and N256E), as well as Gai3 DC9,
a mutant expected not to be activated by rhodopsin. Because
GPCR-mediated activation requires an intact G-protein
heterotrimer, we ﬁrst tested whether any of the Gai3 mutants
had altered Gbg binding. Both W211A and F215A abolished Gbg
binding (Fig. 7b) and were excluded from subsequent
experiments. The other mutants that disrupt GIV and DAPLE
binding (K35A, L249H, S252D and N256E) were activated
efﬁciently by rhodopsin, whereas the DC9 mutation completely
abolished it (Fig. 7c). These in vitro results show that GBA
proteins and GPCRs use different molecular mechanisms to
couple to G proteins. We also investigated the effect of different
G proteins mutants in a genetically engineered yeast strain that
lacks endogenous GPCRs and expresses a single Ga subunit
(human Gai3 with the ﬁrst 35 residues (aN) replaced by the
corresponding residues of yeast Gpa1 (Fig. 7d). In this system, the
natural pheromone response pathway that leads to activation of
the ERK-like kinase Fus3 can only be activated by exogenous
GEFs (Fig. 7d). Saccharomyces cerevisiae does not express GoLoco
proteins. We found that GIV and DAPLE activated Gai3 WT and
Gai3 DC9 equally, while activation of Gai3 N256E (NE, see
rationale for the choice of this mutant in Methods) was blunted
(Fig. 7e). Conversely, the human GPCR A2bR equally activated
Gai3 WT and Gai3 N256E while activation of Gai3 DC9 was
completely blunted (Fig. 7f). These results further conﬁrm the
divergence between the mechanisms of GPCR and GBA motif
coupling to G proteins.
Discussion
Here we provide the ﬁrst detailed characterization of the molecular
basis for the activation of trimeric G proteins by non-receptor
GEFs containing a GBA motif. Our conclusions are supported by
consistent results from three independent and complementary
approaches: biophysical (NMR); computational (modelling); and
biochemical (mutagenesis). The major conclusion is that the
mechanism of G-protein activation by GBA motif-containing GEFs
is fundamentally different from the mechanism used by GPCR
GEFs. Although results from such NMR experiments cannot be
directly compared to the available crystal structure of nucleotide-
free G protein in complex with a GPCR4, they can be interpreted
with conﬁdence in light of a wealth of additional information
on the mechanism of GPCR-mediated activation obtained
from experiments using biophysics5–9; biochemistry10,11; and
computational modelling12–14. The current model for GPCRs is
that activation is caused by the simultaneous perturbation of
structural elements that bind both the nucleotide base (b6–a5 and
b5–aG loops) and the nucleotide phosphates (P-loop and SwI).
According to this model, GPCRs bind to the C terminus of
Ga triggering a conformational change through the a5 helix to
perturb the nucleotide base-binding region4,6,10–13. Perturbation
of the phosphate-binding elements is currently explained by two
non-exclusive models: one is that it is a consequence of the
rearrangements of the nucleotide base-binding site4,6,12 while the
other holds that it is caused by GPCR binding to the N terminus of
Ga and subsequent conformational rearrangements transmitted
to the P-loop through the b1 strand10,12. Our results indicate
that in contrast to the GPCR mechanism, GIV does not induce
perturbations in the nucleotide base-binding b6–a5 and b5–aG
loops, but does cause structural changes in the P-loop and SwI
phosphate-binding elements (Figs 2 and 3). Moreover, GIV, as well
as other GBA proteins, binds to a Ga region different from the
GPCR-binding site. The GBA motif docks in a cavity delimited by
the a3/SwII/a3–b5 loop in which the b1 strand lies at the bottom
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Figure 5 | Comparison of GIV and GPCR binding to Gai3. (a) Mapping of GIV-induced NMR perturbations onto the structure of Gai3. The overlay of NMR
perturbations on a structural model of GIV-bound Gai3 was generated as described in Fig. 3. (b) Mapping of GPCR contact sites on the structure of Gai3.
Gai regions contributing to the interaction with GPCRs were extracted from a previously described model of Rhodopsin-Gai1 (ref. 12) and coloured red on
the Gai3 structure model described in a (in blue). (c) Proposed allosteric routes for GIV- and GPCR-mediated acceleration of nucleotide exchange on Ga.
Top, GIV binds to a cleft delimited by the SwII and a3 helix of Ga and induces perturbations in the b1 strand located at the bottom of this cleft that are
allosterically transmitted to the contiguous P-loop in the nucleotide-binding pocket. Bottom, GPCRs engage the C-terminal a5 helix, the a4/b6 loop and the
aN–b1 linker of Ga to transmit conformational changes to the nucleotide-binding pocket via two major routes: (i) to the guanine-binding b6–a5 loop via the
C-terminal a5 helix; and (ii) to the phosphate-binding P-loop via the b1 strand.
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(Fig. 4). The b1 strand directly extends into the P-loop and acts as
an allosteric route to perturb the P-loop on GPCR binding10,12.
We propose that the b1 strand also serves as a conduit to transmit
information from the GIV-binding site to the nucleotide-binding
pocket. GIV altering only a subset of the nucleotide-binding
elements (P-loop/SwI) may be the reason behind the apparent
lower GEF efﬁciency of GIV compared to GPCRs18. Nevertheless,
this also suggests that weakening phosphate binding is sufﬁcient
for GEF-catalysed nucleotide exchange. A recent study14 indicates
that the main driving force for nucleotide release is the structural
rearrangement of the Ras-like domain instead of the separation
between the Ras-like and all-helical domains as previously
suggested4,5,8,10. The same study also provided evidence that
without destabilization of phosphate binding, nucleotides are not
released. However, because GPCRs induce structural rearrange-
ments in all the different nucleotide-binding elements of Ga, it
remained unclear whether weakening of phosphate binding was
necessary or sufﬁcient to accelerate nucleotide exchange. Our
results with the non-receptor GEF GIV highlight the importance of
phosphate binding for nucleotide exchange and suggest that
altering the interaction between GDP phosphates and the P-loop/
SwI is sufﬁcient to promote nucleotide exchange. This mechanism
of G-protein activation regulates signalling in cells, as demonstrated
by GIV-dependent signalling via Gai-GTP26–28 and free
Gbg18,20,27,29. Moreover, GIV and GPCRs activate G-protein
signalling in cells to a similar extent as determined by
bioluminescence resonance energy transfer-based biosensors30.
Thus, the moderate GEF activity of GIV in vitro might be either
an underestimation of its GEF activity in cells or just sufﬁcient to
elicit biological responses. This is in keeping with early observations
for the a2 adrenergic receptor, a bona ﬁde Gi GEF, which showed
moderate GEF activity in vitro (three to sixfold)41,42.
The GBA motif of GIV is present in a long disordered region of
the protein (Supplementary Fig. 4), and the shorter GBA peptide
recapitulated the NMR perturbations caused by GIV-CT
(Supplementary Fig. 3), indicating that the GBA motif is sufﬁcient
to regulate G proteins. The disordered nature of GIV-CT is
intrinsic and not a consequence of the truncation of the protein at
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residue 1,660 since disorder is predicted for the C-terminal 330
residues of the GIV sequence, and larger fragments of GIV can also
recapitulate G-protein binding and/or activation in a GBA motif-
dependent manner18,25. The presence in intrinsically disordered
regions might be a property common to all GBA motifs identiﬁed
to date. For example, the GBA motif of both GBAS-1 and DAPLE
are located in intrinsically disordered regions24,43. In CALNUC,
the GBA motif overlaps with the region corresponding to its
calcium-binding EF hands. However, Gai3 binds to the GBA motif
of CALNUC only when the protein is not calcium-bound19, which
is known to result in high disorder of the region comprising the EF
hands (and the GBA motif)44. Thus, it is possible that the presence
of GBA motifs in intrinsically disordered regions facilitates
their function by making them more readily accessible to the
target G protein.
The molecular mechanism of activation of Ga by GBA
motif-containing proteins has more similarities with
GEF-mediated activation of small G proteins of the Ras family
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conﬁrmed by Ponceau S staining (bottom row). One experiment representative of three is shown. (c) Gai3 mutants that disrupt activation by GIV are
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(black) of rhodopsin. Mean±s.e.m., n¼ 3. (d) Schematic diagram and validation of a yeast-based assay used to monitor G-protein signalling in cells.
A genetically engineered S. cerevisiae strain was used to determine the levels of G-protein activation on expression of exogenous GEFs like GIV and DAPLE
or a GPCR (human A2b receptor) by measuring Fus3 phosphorylation (phospho(pp)ERK antibodies recognize yeast ppFus3). Insert, validation experiment
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One experiment representative of three is shown.
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than GPCR-mediated activation of trimeric G proteins.
First, GBA proteins displace Gbg from the trimeric complex18,20
and exert their GEF activity directly on monomeric Ga
(refs 18–20,25), whereas GPCRs work most efﬁciently as GEFs
on intact Gabg trimers40. Second, GEFs for small G proteins
perturb the phosphate-binding region of the G protein while
leaving the guanine base-binding region mostly unchanged45.
Third, as in the case of GEFs for small G proteins, GBA proteins
bind to a region that overlaps with the site where effectors
and other regulators (like GAPs) bind13, whereas GPCRs bind
to a region that does not overlap.
GBA proteins also differ from the non-receptor GEF Ric-8A.
Although both Ric-8A and GBA proteins activate monomeric
Ga instead of Gabg trimers21, removal of the C terminus of
Ga only abrogates Ric-8A action22. This indicates a different
mode of G-protein binding for Ric-8A that resembles how
GPCR bind. Also, Ric-8A binds preferentially to nucleotide-free
Gai (ref. 22), which again differs from GBA proteins and
resembles GPCRs.
The preference of GPCRs for nucleotide-free G proteins4,21 is
considered an event that favours the progression of the reaction
in the direction of activation. In the case of GIV, the directionality
of the reaction is still ensured by the dissociation from Gai on
GTP binding, but it is unclear why a GEF would bind to
Gai-[GDP] with an afﬁnity comparable to nucleotide-free Gai.
We speculate that such Gai-[GDP] binding would increase the
efﬁciency of this class of GEFs. To activate Gai, GBA proteins
must either displace Gbg from the trimeric complex or engage
transiently formed Gai-[GDP] en route to re-association with
Gbg after a priming cycle of activation. In both scenarios, binding
with higher afﬁnity to Gai-[GDP] would be advantageous
to facilitate GBA-mediated activation. Therefore, we propose
a model to integrate the GBA-mediated mechanism of activation
with the classic G-protein cycle triggered by GPCRs (Fig. 8).
In vitro experiments demonstrate that GIV and DAPLE can
displace Gbg (refs 18,20), and GIV can also induce the rapid
dissociation of the Gabg complex in cells30.
A question that cannot be unambiguously answered at
this point is whether the perturbations observed in the
nucleotide-binding pocket in our NMR experiments are due
to lower GDP occupancy or structural rearrangements of the
GDP-bound form on GIV binding. This is in part because studies
in Gat (ref. 46) and Gai1 (ref. 47; which shares 490% sequence
identity with Gai3) indicate that the NMR spectra of nucleotide-
free Ga do not differ markedly from those of Ga-GDP.
Nevertheless, we favour the interpretation that our NMR
experiments reﬂect changes in GDP-bound G proteins because
they were carried out in the presence of 300 mM GDP, a 3- or
10-fold molar excess over Gai3 (for GIV-CT or GIVpept,
respectively). Since G proteins bind nucleotides with submicro-
molar–nanomolar afﬁnity48,49, we think that it is unlikely that the
GEF activity of GIV will be sufﬁcient to lower it over three orders
of magnitude to result in a marked decrease of nucleotide
occupancy. Moreover, an overall decrease in the nucleotide
occupancy would also be expected to result in perturbations in
the guanine-binding elements of the nucleotide-binding pocket,
which we do not observe. Thus, our results probably reﬂect the
structural rearrangements that precede the release of nucleotide.
Regardless of the exact interpretation, it is possible that the
observed structural perturbations would be even more marked in
the absence of GDP. This would be in agreement with previous
hydrogen–deuterium exchange experiments showing that Gs in
complex with the b2AR complex in the presence of excess GDP
(1mM) undergoes changes in the exact same regions as the
nucleotide-free complex but of lower magnitude (Supplementary
Figs 2 and 9 of ref. 10).
The combined NMR, computational and mutagenesis analyses
presented here provide a detailed view of the structural features
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that govern the GBA–Ga interaction. Because some GBA
proteins are speciﬁcally dysregulated in disease and disruption
of Ga binding blocks their adverse effects16,20,31, the structural
insights gained here should provide a solid framework for the
development of new pharmacological agents. On the basis of our
results, such agents would not be expected to interfere with
GPCR-mediated activation, and previous data indicate that GIV’s
GBA motif binding can be disrupted by mutagenesis of
Ga without affecting binding to other G-protein-interacting
partners like GPCRs, Gbg, RGS proteins or GoLoco guanine-
nucleotide dissociation inhibitors25. Although effectors bind to
the SwII/a3 region of Ga, they do so only in its GTP-bound
conformation. This conformation is different from that adopted
by Ga-GDP3, the form to which GBA motifs bind, thereby
providing room for speciﬁcity in targeting. However, a major
challenge will be to identify drugs that can discriminate among
different GBA proteins. Such efforts would require atomic
resolution structures to exploit small differences in the binding
mode among distinct GBA proteins.
Methods
Preparation of nucleotide-free Gai3 and pull-down assay. His-tagged rat
Gai3 cloned in a pET28b vector was puriﬁed from BL21(DE3) bacteria
(Life Technologies) after isopropyl-[beta]-D-thiogalactoside (IPTG) induction18,25.
Nucleotide-free Gai3 was prepared by promoting nucleotide release with high
concentrations of ammonium sulfate in the presence of glycerol22,50. For this, His-
Gai3 was run through a Superdex S75 column equilibrated with 20mM Tris-HCl
(pH 7.4), 20mM NaCl, 1mM MgCl2, 1mM dithiothreitol (DTT), 10 mM GDP and
5% (v/v) glycerol. A volume of 200 ml of His-Gai3 at B5 mM were loaded on a
Sephadex G-25 column (10ml) equilibrated with 1M ammonium sulfate, 20% (v:v)
glycerol (pH 6) and the protein eluted at room temperature with the same buffer.
Protein-containing fractions were pooled (B400–600 ml) and incubated overnight
at 4 C. After concentration to B100–200 ml, the sample was applied to a second
Sephadex G-25 column (10ml) equilibrated with 50mM Tris-HCl (pH 8.1),
150mM NaCl, 2mM MgCl2, 1mM EDTA, 2mM DTT, 20% (v:v) glycerol and
0.04% (w:v) C12E10, and eluted with the same buffer. Protein-containing fractions
were pooled and subsequently separated in three aliquots of 125 ml. One aliquot
was kept at 4 C (nucleotide-free Gai3, and Gai3-[ ]), the other two were incubated
at 30 C for 3 h in the presence of 100 mM GDP or 100mM GDP plus 100mM AlCl3
and 10mM NaF to generate GDP-loaded Gai3 (Gai3-[GDP]) or GDP/AlF4 -
loaded Gai3 (Gai3-[GTP]). Samples were cooled down to 4 C and centrifuged for
10min at 14,000g. A volume of 30ml of the His-Gai3-containing supernatants
were used for pull-down assays in which the proteins immobilized on glutathione–
agarose beads were 10 mg of glutathione S-transferase (GST), GST-GIV (residues
1,671–1,755, containing its GBA motif)20, GST-GAIP25 or GST-Ric-8A (residues
12–491, a plasmid generously provided by Stephen Sprang, University of
Montana)22. Binding reactions were carried out for 2.5 h at 4 C in a ﬁnal volume
of 300 ml of 50mM Tris-HCl (pH 8.1), 150mM NaCl, 2mM MgCl2, 1mM EDTA,
2mM DTT, 20% (v:v) glycerol and 0.04% (w:v) C12E10, or the same buffer
supplemented with 100mM GDP or 100 mM GDP plus 100 mM AlCl3 and 10mM
NaF. Glutathione–agarose beads were washed with the same buffers and resin-
bound proteins eluted with Laemmli sample buffer and separated by SDS–PAGE.
After transfer to polyvinylidene diﬂuoride (PVDF) membranes, GST-fused
proteins were visualized by Ponceau S staining and His-Gai3 detected by
immunoblotting with mouse anti-polyHis-Tag primary antibodies (1:2,500, Sigma,
H1029) and goat anti-mouse IRDye 800F(ab0)2 secondary antibodies (1:10,000,
Li-Cor) using an Odyssey Infrared Imaging System (Li-Cor Biosciences). Equal
volumes of the starting material of Gai3-[ ], Gai3-[GDP] and Gai3-[GTP] were
run to verify equivalent loading of protein in the binding reactions. Images were
processed using the Image J software (NIH) and assembled for presentation using
Photoshop and Illustrator softwares (Adobe). Images of uncropped scans of
immunoblots and protein gels are provided in Supplementary Fig. 9.
Co-immunoprecipitation. HEK293T cells (American Type Culture Collection)
were grown at 37 C in DMEM supplemented with 10% FBS, 100Uml 1
penicillin, 100 mgml 1 streptomycin, 1% L-glutamine and 5% CO2. DNA plasmids
encoding for C-terminally 3xFLAG-tagged Gai3 (ref. 25) or an empty plasmid
(p3xFLAG-CMV-14) were transfected using the calcium phosphate method in
10 cm dishes. The DNA amount for the Gai3 N269D plasmid was threefold (12 mg)
of that for Gai3 WT (4mg) to equalize their expression levels. Cells were collected
48 h after transfection by gently scrapping in PBS, centrifuged and resuspended in
1ml of lysis buffer (20mM HEPES (pH 7.2), 5mM Mg(CH3COO)2, 125mM
K(CH3COO), 0.4% (v:v) Triton X-100, 1mM DTT, 10mM b-glycerophosphate
and 0.5mM Na3VO4 supplemented with a protease inhibitor cocktail
(Sigma; catalogue #S8830)) and cleared (14,000g for 10min) before use. Lysates
were supplemented with 1 mg of puriﬁed GST-Ric-8A (12–491)22 and 2 mg of
mouse anti-FLAG antibody (Sigma F1804), and incubated for 4 h at 4 C with
rotation. BSA-blocked Protein G agarose beads (Thermo-Scientiﬁc) were
added and tubes incubated for additional 90min at 4 C. Beads were washed
four times (4.3mM Na2HPO4, 1.4mM KH2PO4, pH 7.4, 137mM NaCl,
2.7mM KCl, 0.1% (v/v) Tween 20, 10mm MgCl2, 5mm EDTA and 1mm DTT)
and immunoprecipitated proteins eluted by boiling in Laemmli sample buffer.
Proteins were separated by SDS–PAGE, transferred to PVDF membranes
and immunoblotted with rabbit anti-GIV serum (1:500)51, rabbit anti-GST
(1:500, Santa Cruz Biotechnology Z-5), mouse anti-FLAG (1:1,000) and mouse
a-tubulin (1:2,500) primary antibodies followed by incubation with goat anti-rabbit
and goat anti-mouse Alexa Fluor 680 or IRDye 800F(ab0)2 secondary antibodies
(1:10,000) and imaging with an Odyssey Infrared Imaging System. Images were
processed using the Image J software (NIH) and assembled for presentation using
Photoshop and Illustrator software (Adobe).
Puriﬁcation of proteins and synthesis of peptides for NMR. Full-length human
Gai3 (UNIPROT entry P08754) cloned in a pET24d(þ ) plasmid (a generous gift
from Ichio Shimada, University of Tokyo) was used to purify the protein used in
NMR experiments39,47. For this, protein expression was induced in BL21 Rosetta
(Life Technologies) cell cultures with 1mM IPTG for 16 h at 23 C in a modiﬁed
M9 minimal medium containing 1 g l 1 15N-NH4Cl, 2 g l 1 2H-13C-glucose and
1 g l 1 of 2H-13C-15N Celtone base powder in 2H2O with 30mg l 1 kanamycin
and 34mg l 1 chloramphenicol. The pelleted cells were lysed by sonication in
50mM Tris, 200mM NaCl, 100mM KCl and 1mM DTT at pH 8.0, and the
supernatant was loaded on a Ni2þ -loaded His-Trap FF column. The fractions were
eluted with the same buffer plus 20 mM GDP and 500mM imidazole, and the
N-terminal His-tag was cleaved with a GST-fusion of the HVRV3C protease (using
a 8.3:1 mass ratio) during an overnight dialysis at 4 C to remove imidazole. This
sample was loaded again on a His-Trap column and the unbound fraction was
loaded on a GST-Trap column to remove the protease. The ﬂow-through was
concentrated by ultraﬁltration and further puriﬁed by gel ﬁltration on a Superdex
200 in 10mM HEPES, 150mM NaCl, 1mM DTT and 20 mM GDP at pH 7.0.
Protein integrity was veriﬁed by mass spectrometry. Between 5 and 9mg of protein
per litre of culture were obtained.
His-tagged human GIV residues 1,660–1,870 (GIV-CT; residue numbers refer
to the sequence in UNIPROT entry Q3V6T2-3) cloned in pET28b (ref. 25) was
expressed in Escherichia coli BL21(DE3) by isopropyl-b-D-thiogalactoside
induction. The pellet of a 30ml saturated culture of BL21 cells in Luria-Bertani
medium was used to inoculate 1 l of an autoinducible ZYP-5052 medium52 with
30mg l 1 kanamycin. Cultures were grown for 2 h at 37 C and then for 16 h at
20 C. Initial tests indicated that only a small fraction of the induced protein was
soluble. To improve the efﬁciency of the immobilized metal ion chromatography
puriﬁcation of the soluble protein, the periplasmic material was removed before cell
lysis53. The pelleted cells of 6 l of bacterial culture were then sonicated in 50mM
sodium phosphate (pH 7.4) with 300mM NaCl and protease inhibitors. The
soluble protein was captured on a 5ml HiTrap Chelating HP column loaded with
Co2þ ions in the same buffer and eluted with a gradient from 20 to 500mM
imidazole in 40 column volumes. Protein-containing fractions were pooled and
imidazole was removed (by means of a HiPrep Desalting column) before injection
in a 1ml HiTrap column loaded with Ni2þ ions. On protein elution using the
same gradient as in the previous chromatography, two overlapping peaks
corresponding to two proteins with a small difference in apparent molecular weight
(as seen in SDS–PAGE) were pooled and the proteins were further separated
on a Superdex 200 16/60 column run with 20mM sodium phosphate (pH 7.4),
500mM NaCl and 1mM DTT. By mass spectrometry peptide ﬁngerprinting, we
identiﬁed the protein eluting at 78ml as GIV, and MALDI was consistent with the
calculated mass of the CT fragment with the N-terminal His-tag but lacking the
initial methionine. The yield was 0.2mg of pure protein per litre of culture. The
uniformly 15N-labelled protein was produced in the same way but growing the cells
in autoinducible medium containing 1.3 g l 1 15N-NH4Cl.
A peptide corresponding to GIV amino acids 1,671–1,696
(KTGSPGSEVVTLQQFLEESNKLTSVQ) was synthesized using the in situ
neutralization protocol for Boc-Solid Phase Peptide Synthesis54 on a p-methylbenz-
hydrylamine resin (Novabiochem, 0.67mmol g 1, 100–200 mesh). Following
chain elongation, the peptide was cleaved from the resin using a solution of
hydroﬂuoric acid containing a 5% of anisole for 1 h at 0 C. Next, the solution was
removed under vacuum and the resulting residue crushed out with Et2O and
ﬁltered. The collected solid was redissolved in a 50% CH3CN/H2O solution
containing 0.1% of triﬂuoroacetic acid (TFA), frozen down and lyophilized. The
crude peptide was puriﬁed by reverse phase-HPLC in a Waters X-Bridge
C18 (19 100mm) column at a ﬂow of 20mlmin 1 using H20 (0.1% TFA)
and CH3CN (0.1% TFA) as eluents. The identity and ﬁnal purity (497%)
of the peptide was determined by analytical reversed phase HPLC and mass
spectrometry (electrospray ionization-time of ﬂight, ESI-TOF).
NMR spectroscopy. All NMR data were measured on a Bruker Avance III
800MHz (18.8 T) spectrometer equipped with a cryogenically cooled triple
resonance z-gradient probe, processed with Topspin (Bruker) and analysed
with Sparky. Proton chemical shifts were referenced to internal 2,2-dimethyl-2-
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silapentane-5-sulfonate (DSS, 0.00 p.p.m.), and 13C and 15N chemical shifts
were indirectly referenced to DSS55. Gai3 spectra were recorded at 30 C on
2H-13C-15N–Gai3 samples with a threefold molar excess of GDP in 10mM HEPES
(pH 7.0) with 10mM MgCl2, 5mm DTT, 0.01% NaN3 and 5% 2H2O. The samples
were prepared by mixing different amounts of Gai3 and GIV-CT from stocks in
the corresponding gel ﬁltration buffers followed by three cycles of fourfold dilution
in the NMR buffer and concentration by ultraﬁltration using 10 kDa cut-off
membranes. Protein solubility limited the Gai3 concentration of the samples to
100mM (free and bound to GIV-CT) or 32 mM (bound to the 1,671–1,696 GIV
peptide). 1H–15N TROSY and HNCO spectra of Gai3 allowed transferring most of
the assignments of the protein backbone resonances deposited in the
BiomagResDataBase entry 19015. We observed, however, a systematic offset of 0.09
and  1.1 p.p.m. in our spectra with respect to the published 1H and 15N chemical
shifts, respectively. The assignment of Gai3 resonances in the presence of a twofold
molar excess of GIV-CT was done based on 1H–15N TROSY, HNCO and HNcoCA
spectra (the latter one, however, lacking many signals because of its lower
sensitivity). The assignment of Gai3 resonances in the presence of a ﬁvefold molar
excess of GIV fragment 1,671–1,696 was achieved from the joint analysis of an
HNCO and 1H–15N TROSY spectra recorded along a titration (at molar ratios 1:0,
1:0.2,1:0.5, 1:1, 1:2 and 1:5). The stepwise addition of the fragment from a 5mM
stock in NMR buffer with 50% 2H-dimethylsulfoxide (DMSO; necessary to
solubilize the peptide) resulted in a 3% DMSO concentration at the last point of the
titration. On the basis of numerous observations on other proteins, we assume that
this concentration of DMSO is too low to signiﬁcantly affect the chemical shifts of
protein amide protons56. The CSPs were computed as the weighted average
distance between the backbone amide 1H and 15N chemical shifts in the free and
bound states57. To compare the intensity of Gai3 signals in different TROSY
spectra, the absolute values were divided by the intensity of the C-terminal Y354,
a narrow isolated signal and one of the most intense, which remained essentially
unchanged on GIV binding. The intensity ratios (Iratio) for each signal were
calculated by dividing the normalized intensity in the free form (Ifree) by the
normalized intensity in the bound form (Ibound). For those signals in which the
Ibound waso1% of the Ifree, it was treated as 1% for all subsequent calculations and
representations (that is, Iratio¼ 100, Log10(Iratio)¼ 2).
GIV-CT 1H–15N HSQC spectra were recorded at 25 C on a 125 mM sample in
PBS (pH 5.5) with 0.5mM DTT, 5% 2H2O and 20mM DSS.
Circular dichroism. Circular dichroism measurements were performed on a Jasco
J-810 spectropolarimeter (JASCO, Tokyo, Japan). The circular dichroism spectrum
was recorded on a GIV-CT protein sample 8.4 mM in PBS (pH 7.0) with 0.2mM
DTT in a 0.2 cm path length quartz cuvette at 25 C. The thermal denaturation
curve from 5 to 95 C was recorded on the same protein sample and cuvette by
increasing temperature at a rate of 1 Cmin 1 and measuring the change in
ellipticity at 222 nm.
Modelling of the GIV–Gai3 complex. A model of human Gai3 bound to the GIV
GBA motif (residues 1,678–1,696) was generated by homology in combination with
iterative stages of ab initio folding, protein–protein docking and reﬁnement.
Independent models of Gai3 and GIV–GBA (residues 1,678–1,688) were ﬁrst built
via homology from the X-ray crystal structure of human Gai1 bound to the KB-752
synthetic GEF peptide using ICM version 3.8-3 (Molsoft LLC., San Diego, CA).
The human Gai3 (NCBI accession: P08754) and GIV (NCBI accession: BAE44387)
sequences were aligned to those of Gai1 or the KB-752 peptide and separately
threaded through the corresponding 3D subunit structures of the Gai1:KB752
complex (PDB: 1Y3A, chains B and F, respectively). Before model building,
hydrogen was added to the 1Y3A parent structure and the isomeric/tautomeric
state and orientation of side chains was optimized with ICM to ﬁnd the best global
hydrogen bond networks and local energetics. Subsequent nonconserved side-chain
conformation optimization and loop prediction (residues 112–117 on Gai3) for the
model were performed by the biased probability Monte Carlo ICM method58–60,
which reﬁnes the global energy with respect to ECEPP/3 and solvation energy
terms. N- and C-terminal extensions for Gai3 beyond the alignment coverage were
modelled de novo by extending the existing structure as helical segments then
minimizing side chains as above.
To model the Gai3:GIV interaction, protein–protein docking of the GIV–GBA
peptide (residues 1,678–1,688) and Gai3 models was performed with ICM using
a rigid-body two-stage fast Fourier transform method followed by ﬂexible reﬁnement
of ligand/receptor interface residues61. To extend the model for inclusion of GIV
residues 1,678–1,696, eight additional amino acids were added to the C terminus of
the top-scoring GIV–GBA conformation from the docking solutions above. The
residues added to the complex were populated in a standard starting covalent
geometry with free torsion angles, and their Gai3-engaging conformation was
simulated ab initio with ICM using the biased probability Monte Carlo-based
approach. Simulations were conducted within a rigid-receptor context at 300K in
continuous dielectric solvent during which GIV residues 1,678–1,687 were tethered
to their protein–protein docking solution while the backbone and side chains of the
extended residues were freely ﬂexible. The extended GIV–GBA peptide was removed
from the receptor and re-docked as above to conﬁrm that an energetically favourable
solution had been found. A fragment-guided molecular dynamics simulation was
then used to improve the modelled complex’s local geometry by relaxing steric
strains and to optimize torsion angles and hydrogen-bonding networks62. FoldX
version 3.0 RepairPDB feature was next used to identify and repair any remaining
high-energy side-chain conformations63,64. Per-residue energy contributions
(kcalmol 1) to the stability of the modelled complex were estimated with
FoldX-SequenceDetail by calculating the differences (DDG) between the GIV-bound
complex and monomeric Gai3 residues at pH 7.0, 0.05M ionic strength and 298K.
Those residues that remained 4þ 1 s.d. in the free energy change (DDG) between
the Gai3 monomer and the Gai3:GIV complex were considered to be strained, and
their side chains were individually optimized with respect to their local environment
as a ﬁnal round of reﬁnement with ICM as described above. GDP was placed within
the ﬁnal model based on the 1Y3A coordinates and neighbouring side chains
surrounding the ligand were optimized. Model images were generated with PyMOL
Molecular Graphics System (Schro¨dinger, LLC).
Puriﬁcation of Gai3 mutants for biochemical studies. Human Gai3 was
expressed from the same plasmid as described for the NMR studies and puriﬁed as
an uncleaved His-tagged protein. Pelleted bacteria from 1 l of culture were
resuspended in 25ml of buffer (50mM NaH2PO4, pH 7.4, 300mM NaCl, 10mM
imidazole, 25 mM GDP and 1% (v:v) Triton X-100 supplemented with protease
inhibitor cocktail (leupeptin 1 mM, pepstatin 2.5 mM, aprotinin 0.2 mM and
phenylmethylsulfonyl ﬂuoride 1mM)). After sonication (four cycles, with pulses
lasting 20 s and with 1min interval between pulses to prevent heating), lysates were
centrifuged at 12,000g for 20min at 4 C. Solubilized proteins were afﬁnity-puriﬁed
on HisPur Cobalt Resin (Pierce) and eluted with lysis buffer supplemented with
250mM imidazole. The buffer was exchanged for 20mM Tris-HCl, pH 7.4, 20mM
NaCl, 1mM MgCl2, 1mM DTT, 10mM GDP and 5% (v/v) glycerol using a HiTrap
Desalting column (GE Healthcare). Protein samples were stored at  80 C.
Gai3-limited proteolysis assay. Human His-Gai3 (0.25mgml 1) was incubated
for 150min at 30 C in buffer (20mM Na-HEPES, pH 8, 100mM NaCl, 1mM
EDTA, 10mM MgCl2, 1mM DTT and 0.05% (w:v) C12E10) supplemented with
GDP (30 mM) or GTPgS (30 mM). After incubation trypsin was added to the tubes
(ﬁnal concentration 6.25 mgml 1) and samples were incubated for 10min at 30 C.
Samples were rapidly transferred to ice and reactions stopped by the addition
of Laemmli sample buffer and boiling for 5min. Proteins were separated by
SDS–PAGE and stained with Coomassie blue.
In vitro protein-binding assays with GST-fused proteins. Binding of Gai3
mutants to GST-fused GIV or DAPLE was determined by a pull-down assay19,25.
A unit of 10mg of GST, GST-GIV (1,671–1,755)20 or GST-DAPLE (1,650–1,745,
created by cloning from Kazusa’s clone fh14721 (KIAA1509) into pGEX-4 T-1)
were immobilized on glutathione agarose beads for 90min at room temperature in
PBS (B1.25 mM ﬁnal concentration in the binding reactions). Beads were washed
twice with PBS, resuspended in 250ml of binding buffer (50mM Tris-HCl, pH 7.4,
100mM NaCl, 0.4% (v:v) NP-40, 10mM MgCl2, 5mM EDTA, 2mM DTT and
30 mM GDP) and incubated 4 h at 4 C with constant rotation in the presence of
His-tagged Gai3 WT or mutants (B1 mM ﬁnal concentration). Beads were washed
four times with 1ml of wash buffer (4.3mM Na2HPO4, 1.4mM KH2PO4, pH 7.4,
137mM NaCl, 2.7mM KCl, 0.1% (v/v) Tween-20, 10mM MgCl2, 5mM EDTA,
1mM DTT and 30mM GDP) and resin-bound proteins eluted with Laemmli
sample buffer by incubation at 37 C for 10min. Proteins were separated by
SDS–PAGE and stained with Coomassie blue.
Fluorescence polarization-based peptide-binding assays. Fluorescently labelled
peptides derived from human GIV (residues 1,671–17,01, KTGSPGSEVVTLQ
QFLEESNKLTSVQIKSSS), DAPLE (residues 1,662–1,695, SASPSSEMVTLEEF
LEESNRSSPTHDTPSCRDDL) or RGS12 (residues 1,185–1,221, DEAEEFFELIS
KAQSNRADDQRGLLRKEDLVLPEFLR) were synthesized following a protocol as
described above in ‘Puriﬁcation of proteins and synthesis of peptides for NMR’
with minor modiﬁcations. Brieﬂy, following chain elongation 5,6-carboxy-
ﬂuorescein was activated with HATU and coupled to the resin-bound peptide at
65 C for 1 h to yield the ﬂuorescein-labelled peptides. The remaining steps were
carried out as described above. Fluorescence polarization measurements were
carried out in 384-well plates (Black OptiPlate-384F, Perkin Elmer). G protein
(0–8 mM) and peptide (0.025 mM) were mixed at room temperature for 10min
in a ﬁnal volume of 20ml of binding buffer (50mM Tris-HCl, pH 7.4,
100mM NaCl, 0.4% (v:v) NP-40, 10mM MgCl2, 5mM EDTA, 2mM DTT and
30 mM GDP). Fluorescence polarization (excitation 485±10 nm/emission
528±10 nm) was measured every 2min for 30min at room temperature in
a Biotek H1 synergy plate reader to ensure that the signals were stable in time.
Fluorescence polarization at different times was averaged, normalized and ﬁtted to
a one site binding hyperbola to determine the equilibrium dissociation constant
(Kd). For mutants not reaching binding saturation, the maximal binding of
Gai3 WT measured in the same experimental set was considered 100% binding
for normalization.
GTPase and GTPcS-binding assays with GIV and DAPLE. Steady-state GTPase
activity was measured by release of radioactive phosphate and GTPgS binding by
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retention of radioactive nucleotide on ﬁlters19,25. Human His-Gai3 WT or mutants
(100 nM ﬁnal concentration) were pre-incubated with His-GIV-CT
(residues 1,660–1,870 (ref. 25), 3 mM ﬁnal concentration) or a DAPLE-derived
peptide (residues 1,662–1,695, SASPSSEMVTLEEFLEESNRSSPTHDTPSCRDDL,
30mM ﬁnal concentration) for 15min at 30 C in assay buffer (20mM Na-HEPES,
pH 8, 100mM NaCl, 1mM EDTA, 25mM MgCl2, 1mM DTT and 0.05% (w:v)
C12E10). GTPase and GTPgS-binding reactions were initiated at 30 C by adding an
equal volume of assay buffer containing 1 mM [g-32P]GTP (B50 c.p.m. fmol 1)
or 1 mM [35S] GTPgS (B50 c.p.m. fmol 1), respectively. GTPase reactions were
stopped at 15min in duplicates by mixing 25 ml of the reaction with 975ml of
ice-cold 5% (w/v) activated charcoal in 20mM H3PO4, pH 3. Samples were then
centrifuged for 10min at 10,000g, and 500ml of the resultant supernatant were
scintillation-counted to quantify the amount of [32P]Pi released. Background
[32P]Pi detected at 15min in the absence of G protein was subtracted from
each reaction (o5% of the counts detected in the presence of G proteins).
GTPgS-binding reactions were stopped at 15min in duplicates by addition of 3ml,
ice-cold wash buffer (20mM Tris-HCl, pH 8.0, 100mM NaCl and 25mM MgCl2)
followed by rapid ﬁltration through BA-85 nitrocellulose ﬁlters (GE Healthcare).
Filters were washed with 4ml of the same buffer, dried and subjected to liquid
scintillation counting. Background [35S]GTPgS binding to the ﬁlters at 15min in
the absence of G protein was subtracted from each reaction (o5% of the counts
detected in the presence of G proteins). GTPase activity and GTPgS binding at
15min are within the linear region of the initial rate of the reactions19,25. For both
assays, GEF-mediated activation was expressed as per cent of the basal activity
(GTPase hydrolysis or GTPgS binding) of each His-Gai3 protein in the absence of
GIV or DAPLE.
Synthesis of peptide libraries and Gai3 overlay. Libraries of immobilized
peptides were produced by automatic SPOT synthesis on continuous cellulose
membrane supports (Whatman 50 cellulose membranes) using Fmoc
(ﬂuoren-9-ylmethoxycarbonyl) chemistry with the AutoSpot-Robot ASS 222
(Intavis Bioanalytical Instruments AG)65. Individual peptide–cellulose complexes
were solubilized and re-spotted on Celluspot slides for subsequent probing. Slides
were primed in binding buffer (4.3mM Na2HPO4, 1.4mM KH2PO4, pH 7.4,
137mM NaCl, 2.7mM KCl, 5mM MgCl2, 1mM DTT, 30 mM GDP and 1% (v:v)
TX100) and blocked for 1 h in the same buffer supplemented with 5% (w:v) BSA.
Slides were incubated for 2 h at room temperature with rat His-Gai3 at 20mgml 1
(B0.5 mM) in the same buffer. After four washes, slides were sequentially
incubated with primary (rabbit anti-Gai3, 1: 250; 90min) and secondary
(goat anti-rabbit Alexa Fluor 680, 1:10,000; 60min) antibodies. Images were
acquired in an Odyssey infrared scanner (Li-Cor), processed using the Image J
software (NIH) and assembled for presentation using Photoshop and Illustrator
softwares (Adobe).
Gbc-binding assays. Gbg was puriﬁed from bovine retinas, which are primarily
composed of Gb1g1 by puriﬁcation of holotransducin from rod outer segment
(ROS) membranes isolated from dark-adapted bovine followed by separation of the
Gb1g1 complex from the a-subunit of transducin on a Hitrap Blue-sepharose
column (GE healthcare), and further puriﬁcation by anion exchange chromato-
graphy using a Hitrap-Q column66,67.
For binding assays, Gb1g1 (100 nM ﬁnal) was incubated in the absence or
presence of human His-tagged Gai3 WT or mutants (50 nM ﬁnal) in 250ml of
binding buffer (50mM Tris-HCl, pH 7.4, 100mM NaCl, 0.4% (v:v) NP-40, 5mM
MgCl2, 10mM imidazole, 0.1mgml 1 BSA, 1mM DTT and 30 mM GDP) for 4 h
at 4 C with rotation. A volume of 25 ml of BSA-blocked HisPur cobalt resin
(Pierce) were added to each tube and the incubation continued for 90min. Beads
were washed four times with 1ml of binding buffer and resin-bound proteins
eluted by adding Laemmli sample buffer supplemented with 100mM EDTA and
boiling for 5min. Proteins were separated by SDS–PAGE, transferred to PVDF
membranes and immunoblotted with rabbit anti-Gai3 (1:500, Santa Cruz
Biotechnology C-10) and anti-panGb (1:250, Santa Cruz Biotechnology M-14)
primary antibodies followed by incubation with goat anti-rabbit Alexa Fluor
680 (1:10,000, Life Technologies) secondary antibodies and imaging with an
Odyssey Infrared Imaging System (Li-Cor Biosciences).
Steady-state GTPase assays with rhodopsin. ROS membranes washed with urea
were prepared as described earlier and used as the source of rhodopsin67. Human
His-tagged Gai3 WT and mutants (20–25 mM) were incubated overnight at 4 C
with twofold excess Gb1g1 in 20mM Tris-HCl, pH 7.4, 20mM NaCl, 1mM MgCl2,
1mM DTT, 10 mM GDP and 5% (v/v) glycerol. Bovine rhodopsin was freshly
solubilized from urea-washed ROS membranes in assay buffer (20mM HEPES, pH
7.5, 100mM NaCl, 5mM MgCl2, 1mM DTT and 0.01% (w:v) dodecylmaltoside)
for each experiment. Gai3/Gb1g1 (100/200 nM ﬁnal) and rhodopsin (20 nM ﬁnal)
were incubated in ice for 30min under ambient light in assay buffer. Reactions
were initiated at 30 C by adding an equal volume of assay buffer containing 1 mM
[g-32P]GTP (B50 c.p.m. fmol 1) and stopped in duplicates by mixing 25 ml of the
reaction with 975ml of ice-cold 5% (w/v) activated charcoal in 20mM H3PO4,
pH 3. Samples were then centrifuged for 10min at 10,000g, and 500ml of the
resultant supernatant were scintillation-counted to quantify the amount of
[32P]Pi released. Background [32P]Pi detected at 15min in the absence of G protein
was subtracted from each reaction (o5% of the counts detected in the presence
of G proteins). Results were expressed as per cent of the activity of Gi3 WT
without rhodopsin.
G-protein activation assay in yeast. The previously described S. cerevisiae strain
CY1316 (ref. 68; MATa gpa1D far1D fus1p-HIS3 ste14:trp1:LYS2 ste3D lys2 ura3
leu2 trp1 his3 can1; kindly provided by James Broach, Penn State University) was
used for experiments with GIV and DAPLE and strain MMY11 (ref. 69; MATa
gpa1D far1D fus1p-HIS3 ste2D sst2D FUS1-lacZ ura3 trp1 his3 can1; kindly
provided by Simon Dowell, Glaxo-Smith-Kline) for the experiments with A2b
receptor. The native G-protein-dependent pheromone response pathway is
similarly modiﬁed in both strains: the pheromone-activated GPCR (Ste2 or Ste3),
endogenous Ga-subunit (Gpa1) and the cell cycle arrest-inducing protein far1 are
deleted. In MMY11, the G-protein inhibitor Sst2 is also deleted. Both strains were
transformed with a centromeric plasmid (CEN TRP) encoding a chimeric yeast
Gpa1(1–41)-human Gai3 (36–354) protein under the control of the endogenous
Gpa1 promoter68 (courtesy of Mary Cismowski, Nationwide Children’s Hospital)
using the lithium acetate method70. In these strains, the pheromone response
pathway can be upregulated by the ectopic expression of activators of human Gai3
and does not result in the cell cycle arrest that occurs in the native pheromone
response68,69. CY1316-derived strains were transformed with pYES2 plasmids
(2 mm, URA3) encoding for GIV (residues 1,660–1,870, between BglII/EcoRI) or
DAPLE (residues 1,650–1,880, between BamHI/NotI with an N-terminal myc-tag)
and double transformants selected in SD-Trp-Ura media. Individual colonies
were inoculated into 3ml of SDGalactose-Trp-Ura and incubated overnight at
30 C to induce the expression of the proteins of interest under the control of the
galactose-inducible promoter of pYES2. This starting culture was used to inoculate
20ml of SDGalactose-Trp-Ura at 0.3 OD600. Exponentially growing cells
(B0.7–0.8 OD600, 4–5 h) were pelleted to prepare samples for immunoblotting
(see below). MMY11-derived strains were transformed with pDT-PGK plasmids
(2 mm, URA3) encoding for human A2bR WT and A2bR G135A/I197L/Y202N
(courtesy of Ad P. IJzerman, Leiden University), a mutant that constitutively
activate G proteins in the absence of agonist71. These strains were processed as
described above except that the media contained glucose instead of galactose.
Yeast protein samples for immunoblotting were prepared by acid lysis and
precipitation followed by neutralization and solubilization70. Pellets corresponding
to 5 OD600 were washed once with PBSþ 0.1% BSA and then resuspended in
150 ml of lysis buffer (10mM Tris-HCl, pH 8.0, 10% (w:v) trichloroacetic acid,
25mM NH4OAc and 1mM EDTA). A volume of 100ml of glass beads was added
to each tube and samples were vortexed at 4 C for 5min. Lysates were separated
from the glass beads by poking a hole in the bottom of the tubes followed by
centrifugation into new tubes. The procedure was repeated after adding 50 ml of
lysis buffer to wash the glass beads. Proteins were then precipitated by
centrifugation (10min, 20,000g) and resuspended in 60ml of solubilization buffer
(0.1M Tris-HCl, pH 11.0, and 3% SDS). Samples were boiled for 5min and
centrifuged for 1min at 20,000g. A volume of 50 ml from the supernatant was
transferred to new tubes containing 12.5 ml of Laemmli sample buffer and boiled
for 5min. Proteins (B15–20 ml per lane) were separated by SDS–PAGE, blocked in
PBS supplemented with 5% BSA and analysed by sequential incubation with
primary and secondary antibodies. Primary antibodies were diluted as follows:
ppERK (rabbit mAb, Cell Signaling #4370), which recognizes yeast ppFus3: 1:2,500;
myc (mouse mAb, Cell Signaling #9B11): 1:1,000, Girdin (Santa Cruz
Biotechnology, T-13); and a-tubulin (Sigma T6074): 1:2,500. Secondary antibodies
(goat anti-mouse IRDye 800F(ab0)2, Li-Cor Biosciences, and goat anti-rabbit Alexa
Fluor 680, Life Technologies) were used at 1:10,000 dilution. Images were acquired
in an Odyssey infrared scanner (Li-Cor), processed with the Image J software
(NIH) and assembled for presentation using Photoshop and Illustrator softwares
(Adobe).
Out of the ﬁve Gai3 mutants tested in the in vitro G-protein activation
experiments with rhodopsin (K35A, L249H, S252D, N256E and DC9), only N256E
and DC9 were tested for different reasons. K35A was excluded because this residue
is right at the boundary between the Gai3 and Gpa1 sequences of the chimera and
for this reason it may yield results that are difﬁcult to interpret. L249H and S252D
were excluded because they displayed enhanced spontaneous activation in yeast.
Data availability. The UniProt accession codes P08754 and Q3V6T2-3, PDB
accession codes 1Y3A and 1GDD, and BMRB accession code 19015 were used in
this study. The coordinates of the ﬁnal model have been deposited in the open
access repository Model Archive (www.modelarchive.org) (10.5452/ma-ayq5v). All
other data are available from the corresponding authors on reasonable request.
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